Skip to main content
. 2023 May 4;480(9):587–605. doi: 10.1042/BCJ20220598

Figure 1. The ERK1/2 inhibitor BVD-523 decreases the abundance of ERK2, but not ERK1.

Figure 1.

(A) HCT116 cells were serum starved for 24 h and then restimulated by addition of 10% (v/v) FBS or were left in complete medium and treated with 3 µM BVD-523 for the indicated times. (B) HCT116 cells were serum starved for 24 h and then restimulated by addition of 10% (v/v) FBS or were left in complete medium and treated with 100 nM Trametinib for the indicated times. (C) HCT116 cells in complete medium were treated with the indicated concentrations of BVD-523 for 24 h. (D) HCT116 cells maintained in complete medium were treated with 3 µM BVD-523 for 24 h. In (A–C) whole cell lysates were fractionated by SDS–PAGE before immunoblotting with the indicated antibodies. In (D) the same control and BVD-523-treated lysates were resolved on a single SDS–PAGE gel that was transferred to PVDF, cut and probed with the indicated ERK1, ERK1/2 or ERK2 antibodies. Results are shown from a single experiment; three experiments gave identical results. Molecular masses in kDa are indicated on the left-hand side.